NANOBIOTIX SPON ADS EACH REP 1 ORD SHS(NBTX)

POST21.400.02+0.09%17:05 EST

21.38+1.32+6.58%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Nanobiotix to Join CAC Indexes
  MT Newswires Live · 2025-12-15
  Nanobiotix to Join CAC Indexes
- NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
  GlobeNewswire · 2025-12-15
  NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
- Nanobiotix Sa : Leerink Partners Raises Target Price to $26 From $24
  THOMSON REUTERS · 2025-11-25
  Nanobiotix Sa : Leerink Partners Raises Target Price to $26 From $24
- Nanobiotix Reports €20.4M In Cash And Cash Equivalents As Of Sept. 30
  Benzinga · 2025-11-25
  Nanobiotix Reports €20.4M In Cash And Cash Equivalents As Of Sept. 30
- Press Release: Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
  Dow Jones · 2025-11-25
  Press Release: Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
- NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
  GlobeNewswire · 2025-11-14
  NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
- NANOBIOTIX to Participate in Jefferies London Healthcare Conference
  GlobeNewswire · 2025-11-12
  NANOBIOTIX to Participate in Jefferies London Healthcare Conference
- Press Release: NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
  Dow Jones · 2025-10-31
  Press Release: NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
- Top Premarket Decliners
  MT Newswires Live · 2025-10-27
  Top Premarket Decliners
- Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer
  TIPRANKS · 2025-10-24
  Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer
- Nanobiotix Up Over 25%, on Track for Record High Close -- Data Talk
  Dow Jones · 2025-10-08
  Nanobiotix Up Over 25%, on Track for Record High Close -- Data Talk
- Stock Track | Nanobiotix (NBTX) Soars 5.07% as Jefferies Triples Price Target
  Stock Track · 2025-10-06
  Stock Track | Nanobiotix (NBTX) Soars 5.07% as Jefferies Triples Price Target
- Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright
  TIPRANKS · 2025-10-02
  Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright
- Stock Track | Nanobiotix Surges 16% Pre-Market on Promising Phase 1 Results for Esophageal Cancer Treatment
  Stock Track · 2025-10-02
  Stock Track | Nanobiotix Surges 16% Pre-Market on Promising Phase 1 Results for Esophageal Cancer Treatment
- Stock Track | Nanobiotix Soars 10.83% on Promising Phase 1 Results for JNJ-1900 in Esophageal Cancer Treatment
  Stock Track · 2025-10-02
  Stock Track | Nanobiotix Soars 10.83% on Promising Phase 1 Results for JNJ-1900 in Esophageal Cancer Treatment
- Stock Track | Nanobiotix (NBTX) Surges 6.51% After-Hours Following Bullish Analyst Rating
  Stock Track · 2025-10-02
  Stock Track | Nanobiotix (NBTX) Surges 6.51% After-Hours Following Bullish Analyst Rating
- Stock Track | Nanobiotix (NBTX) Surges 6.51% After-Hours Following Leerink Partners' Bullish $24 Price Target
  Stock Track · 2025-10-02
  Stock Track | Nanobiotix (NBTX) Surges 6.51% After-Hours Following Leerink Partners' Bullish $24 Price Target
- Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts
  TIPRANKS · 2025-10-02
  Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts
- NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
  GlobeNewswire · 2025-10-02
  NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
- Leerink Partners Sticks to Its Buy Rating for Nanobiotix (NBTX)
  TIPRANKS · 2025-10-01
  Leerink Partners Sticks to Its Buy Rating for Nanobiotix (NBTX)
Company Profile
Company Name
NANOBIOTIX SPON ADS EACH REP 1 ORD SHS
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.nanobiotix.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
- 2025-05-14
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2025-04-02
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2025-03-13
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2024-04-24
  Annual Report
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-09
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2024-02-08
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2024-02-02
  Beneficial Ownership Change
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2023-11-16
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2023-11-09
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2023-11-03
  [Supp]Public Prospectus
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2023-11-02
  [Supp]Public Prospectus
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2023-06-27
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2023-04-24
  Annual Report
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2022-04-08
  Annual Report
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2022-02-14
  Correspondence
  CORRESP [Cover] - Correspondence
  CORRESP [Cover] - Correspondence

1D
5D
Day
Week
Month

Loading ...

High

21.41

Open

21.05

Volume%

0.38

Low

21.02

20.06

T/O Rate

0.02%

To The Moon

NANOBIOTIX SPON ADS EACH REP 1 ORD SHS(NBTX)

Company Profile

Most Discussed